[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-360235-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-360235-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","risk-of-metastasis-and-survival-in-patients-with-t1-2-non-ampullary-duodenal-neuroendocrine-tumors-undergoing-different-treatment-strategies","Risk of metastasis and survival in patients with T1-2 non-ampullary duodenal neuroendocrine tumors undergoing different treatment strategies","","Optimal management of T1-2 non-ampullary duodenal neuroendocrine tumors (NAD-NETs) remains debated, especially for intermediate-sized tumors (11–20 mm) due to limited evidence. Using real-world data from the SEER database, the study quantified metastasis risk and compared long-term survival between endoscopic therapy (ET) and surgical therapy (ST) in T1–2N0M0 NAD-NETs. Metastasis risk predictors were identified and survival outcomes were statistically evaluated after propensity matching.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/risk-of-metastasis-and-survival-in-patients-with-t1-2-non-ampullary-duodenal-neuroendocrine-tumors-undergoing-different-treatment-strategies/360235/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/risk-of-metastasis-and-survival-in-patients-with-t1-2-non-ampullary-duodenal-neuroendocrine-tumors-undergoing-different-treatment-strategies/360235.png","ImageObject",300,407,{"name":42,"@type":43},"Cart","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the study’s primary goal for T1-2 non-ampullary duodenal neuroendocrine tumors (NAD-NETs)?","Question",{"text":63,"@type":64},"To quantify real-world metastasis risk and compare long-term survival after endoscopic therapy versus surgical therapy for T1-2N0M0 NAD-NETs, with focus on intermediate-sized tumors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which factors were associated with higher metastasis risk in the analysis?",{"text":68,"@type":64},"Tumor size (11–20 mm and >20 mm) and muscularis propria invasion were independent predictors of metastasis risk.",{"name":70,"@type":61,"acceptedAnswer":71},"How did long-term outcomes compare between ET and ST for T1-2N0M0 NAD-NETs?",{"text":72,"@type":64},"After propensity matching, long-term prognosis was comparable between ET and ST, including similar 5-year cancer-specific survival and overall survival, with subgroup analyses supporting equivalent survival across measured size ranges.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},360235,1790557337,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Peng et al. Discover Oncology (2026) 17:794 [https://doi.org/10.1007/s12672-026-05013-0](https://doi.org/10.1007/s12672-026-05013-0)  \nDiscover Oncology  \nANALYSIS Open Access  \nRisk of metastasis and survival in patients  with T1-2 non-ampullary duodenal neuroendocrine tumors undergoing different treatment strategies  \nCheng Peng1,2,3†, Wan-shu Chen1,2,3†, Yao-wen Hu 1,2,3, Tian-ming Xu 1,2,3, Peng-guang Yan1,2,3, Xiang Xu1,2,3, Bo-wen Tian1,2,3, Ji Li1,2,3 and Jing-nan Li 1,2,3*  \n†Cheng Peng and Wan-shu Chen have contributed equally to this work.  \n*Correspondence: Jing-nan Li[lijn@pumch.cn](lijn@pumch.cn)  \n1Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China 2Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100005, China  \n3Key Laboratory of Gut Microbiota Translational Medicine Research, Chinese Academy of Medical Sciences, Beijing, China  \nAbstract  \nBackground Optimal management ofT1-2 non-ampullary duodenal neuroendocrine tumors (NAD-NETs) remains controversial, particularly for intermediate-sized tumors (11–20 mm), due to limited evidence. This study aimed to quantify real-world metastasis risk and compare long-term survival after endoscopic therapy (ET) or surgical therapy (ST) forT1-2N0M0 NAD-NETs.  \nMethods Patients were identified from the Surveillance, Epidemiology, and End Results (SEER) database and divided into two cohorts: Cohort A (n = 2101), including T1–2 NAD-NETs for metastasis risk-factor analysis; and Cohort B (n = 1496), including T1–2N0M0 NAD-NETs treated with ET or ST for survival comparison. Multivariable logistic regression was performed to assess factors associated with metastasis risk in Cohort (A) Propensity score matching was performed to balance covariates in Cohort (B) Cancer-specific survival (CSS) and overall survival (OS) were calculated and compared between the ET and ST groups.  \nResults Overall metastasis incidence at diagnosis was 9 .42%(198/2101) . Independent metastasis predictors included tumor size 11–20 mm (OR = 4 . 30, 95% CI:3 .00–6. 16) and > 20 mm (OR = 14 . 65, 95% CI:9 .38–22. 94), and muscularis propria (MP) invasion (OR = 4 . 94, 95% CI:2 .41–10. 74) . Of the 1496 patients with T1-2N0M0 NAD-NETs, the long-term prognosis was comparable between ET and ST (after matching, 5-year CSS:  \n99. 0% vs. 97. 1%, P = 0 . 031; 5-year OS: 84 . 6% vs. 87.4%, P = 0 . 37) . Subgroup analyses confirmed equivalent survival for ET versus ST across those measuring 11–20 mm (CSS 97.4% vs. 98. 1%, P = 0 . 694) and those measuring > 20 mm (CSS 100% both) .  \nConclusion ET provides comparable long-term survival versus surgery forT1-2N0M0 NAD-NETs and ET could be a viable strategy for well-to moderately differentiated NADNETs of 11–20 mm without MP invasion.  \nKeywords Duodenal neuroendocrine tumors, Metastasis risk, SEER, Survival, Treatment strategies  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creat","cbCaij7qDzVBTkED","https://ap.wps.com/l/cbCaij7qDzVBTkED","pdf",1897657,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## NETs and duodenal neuroendocrine tumor classification\n## Controversy in management of NAD-NETs\n## Guideline divergence for intermediate-sized tumors","[{\"question\":\"What is the study’s primary goal for T1-2 non-ampullary duodenal neuroendocrine tumors (NAD-NETs)?\",\"answer\":\"To quantify real-world metastasis risk and compare long-term survival after endoscopic therapy versus surgical therapy for T1-2N0M0 NAD-NETs, with focus on intermediate-sized tumors.\"},{\"question\":\"Which factors were associated with higher metastasis risk in the analysis?\",\"answer\":\"Tumor size (11–20 mm and \\u003e20 mm) and muscularis propria invasion were independent predictors of metastasis risk.\"},{\"question\":\"How did long-term outcomes compare between ET and ST for T1-2N0M0 NAD-NETs?\",\"answer\":\"After propensity matching, long-term prognosis was comparable between ET and ST, including similar 5-year cancer-specific survival and overall survival, with subgroup analyses supporting equivalent survival across measured size ranges.\"}]","Risk of metastasis and survival in patients with T1-2 non-ampullary duodenal neuroendocrine tumors undergoing different treatment strategies | PDF",1790139165,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0dffd16aeb804183e048e2f4bec663bd.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/91c29b51d3d8eac267f3d2698a9e2330.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a49b5dd6d70359804f33457e46f46363.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e66ac1621d79b521d837d0996a316487.webp",980,1306]